Erbitux� (cetuximab) Combined With Chemotherapy Extends Survival From 21 To Nearly 25 Months For KRAS Wild-Type Metastatic Colorectal Cancer Patie Part 2

In the county of colorectal cancer, cetuximab plus irinotecan have be licensed contained by practice of fancy of irinotecan-refractory mCRC in the EU since June 2004. In the UK nevertheless, NICE has for that plea far not conceded cetuximab by means of an prospect here warning sign, on top of the confines it be "not compatible near the uttermost devour of NHS resources".6 NICE is at present review cetuximab for 1st-line use in patients with mCRC and a decree is anticipated in April 2009.7 * CRYSTAL: Cetuximab shared with iRinotecan in productive smudge therapY for metaSTatic colorectAL cancer ** OPUS: OxaliPlatin and cetUximab in firSt-line analysis of mCRC *** EXTREME: ErbituX in 1st-line Treatment of REcurrent or MEtastatic skipper & collar cancer About ERBITUX® ERBITUX® (cetuximab) is an IgG1 monoclonal antibody (mAb) targeted to the Epidermal Growth Factor Receptor (EGFR), and be the first mAb to be licensed for use in colorectal cancer in the EU in June 2004. It is manufactured by Merck Serono.

About KRAS The KRAS gene attitude for a protein baffled in the EGFR pathway - a thorny pathway involved in the steps readdress and inventiveness of cancer. In KRAS wild-type tumour, the KRAS protein is lone initiate in riposte to sure stimulus, such as EGFR signal. Erbitux® works by blocking the EGFR signalling pathway, bar KRAS activation, and subsequent tumour maturity. In mutant KRAS tumours, the KRAS protein is lastingly activated (regardless of EGFR signalling), as a consequence the inhibitory effect of Erbitux® is cheapen in these cases.

About Bowel Cancer Bowel cancer is the third maximum prevailing cancer in the UK, with higher than 36,000 ethnic group diagnose respectively year.8 Five-year life rates for patients with colorectal cancer hold double done the closing moments thirty years and be astonishingly in two shakes of a lamb`s tail linking 47% and 51%.9 About Head and Neck Cancer More than 7,800 people are diagnosed with head and neck cancer in the UK both year, the majority of which return up in the chops, pharynx or idiom.10 About Merck Serono Merck Serono, the investigational polarization for ahead of its circumstance undersized molecules and biopharmaceuticals of Merck, was settled subsequent to the act of Serono and the reconciling of its group with the ex Merck Ethicals Division. Headquartered in Geneva, Switzerland, Merck Serono slaughter upon, develop, produce and commercializes innovative products to abet patients with germ with unmet desires. Our North American business operate in the United States and Canada underneath EMD Serono.